Table 3.

Multispecific NK cell engagers in clinical trials (all stages), as of July 2023

Drug name	Format	Specificity	Indication	Clinical trial	Phase	Sponsor
AFM13	TandAb	CD30/CD16a	HL, NHL	NCT04074746	1/2	Affimed
AFM28	IgG-like ROCK	CD123/CD16a	AML	NCT05817058	1	Affimed
LAVA-051	Gammabody	CD1d/NKT TCR	CLL, MM, AML	NCT04887259	1/2	Lava Therapeutics
IPH6101/SAR443579	ANKET	CD123/CD16/NKp46	AML, MDS	NCT05086315	1/2	Sanofi
IPH6401/SAR445514	ANKET	BCMA/CD16/NKp46	R/R MM	NCT05839626	1/2	Sanofi
CC-92328/DF3001	TriNKET	BCMA/CD16/NKG2D	R/R MM	NCT04975399	1	Celgene (BMS)
CC-96191/DF2001	TriNKET	CD33/CD16/KNG2D	R/R AML	NCT04789655	1	Celgene (BMS)